Folsyra Vitabalans (Folic Acid 1 mg)
Prescription folic acid tablet for folate deficiency and pregnancy support
Quick Facts About Folsyra Vitabalans
Key Takeaways
- Essential during pregnancy: Folic acid supplementation before conception and during early pregnancy reduces the risk of neural tube defects by up to 70%
- Treats folate deficiency anaemia: Folic acid is the first-line treatment for megaloblastic anaemia caused by folate deficiency, restoring normal red blood cell production
- Caution with B12 deficiency: Folic acid can mask the haematological signs of vitamin B12 deficiency, potentially allowing irreversible neurological damage to progress
- Drug interactions matter: Several common medications including methotrexate, phenytoin, and carbamazepine interact with folic acid and require dose adjustment
- Generally very well tolerated: Side effects are rare and usually mild, making folic acid one of the safest prescription vitamin supplements available
What Is Folsyra Vitabalans and What Is It Used For?
Folsyra Vitabalans is a prescription folic acid tablet containing 1 mg of synthetic folic acid (pteroylglutamic acid), the manufactured form of folate (vitamin B9). It is primarily used to treat folate deficiency anaemia and to prevent neural tube defects during pregnancy. Folic acid is classified under ATC code B03BB01 as an antianemic preparation.
Folic acid, also known as vitamin B9, is a water-soluble B vitamin that plays a critical role in numerous metabolic processes within the body. The term "folic acid" specifically refers to the synthetic, oxidised form of folate that is used in supplements and fortified foods. Once ingested, folic acid must be converted to its biologically active form, tetrahydrofolate (THF), through a series of enzymatic reactions primarily occurring in the liver. This active form then serves as a coenzyme in one-carbon transfer reactions that are essential for the synthesis of purines and thymidylate, which are building blocks of DNA and RNA.
The importance of folic acid in human health cannot be overstated. It is indispensable for normal cell division, tissue growth, and the formation of red blood cells. Folate deficiency leads to impaired DNA synthesis, which manifests most prominently in rapidly dividing cells such as those in the bone marrow and the developing fetus. This is why folate deficiency anaemia and neural tube defects represent the two most clinically significant consequences of inadequate folate status.
Folsyra Vitabalans is manufactured by Vitabalans Oy and is available as a 1 mg tablet intended for oral administration. In many countries, folic acid at this dosage strength requires a prescription, although lower-dose supplements (typically 400 micrograms) are available over the counter. The prescription requirement for the 1 mg formulation allows healthcare providers to monitor patients who require higher doses and to ensure that vitamin B12 deficiency has been excluded before initiating treatment.
Primary Indications
The primary clinical indications for Folsyra Vitabalans include:
- Folate deficiency anaemia: Treatment of megaloblastic anaemia resulting from inadequate dietary folate intake, malabsorption syndromes, or increased folate requirements
- Prevention of neural tube defects: Supplementation before conception and during the first trimester of pregnancy to reduce the risk of spina bifida and anencephaly
- Methotrexate co-therapy: Reduction of folate-related side effects in patients receiving methotrexate for rheumatoid arthritis, psoriasis, or other conditions
- Chronic haemolytic anaemias: Prophylaxis against folate deficiency in conditions with increased red blood cell turnover such as sickle cell disease and thalassaemia
- Dialysis patients: Supplementation in patients on haemodialysis or peritoneal dialysis, as dialysis removes folate from the blood
Folate is the naturally occurring form of vitamin B9 found in foods such as green leafy vegetables, legumes, and liver. Folic acid is the synthetic form used in supplements and food fortification. While both serve the same biological function, folic acid has higher bioavailability (approximately 85% from supplements vs. approximately 50% from food sources) and is more stable during storage and processing.
What Should You Know Before Taking Folsyra Vitabalans?
Before taking Folsyra Vitabalans, it is essential to rule out vitamin B12 deficiency, as folic acid can correct the anaemia of B12 deficiency while allowing potentially irreversible neurological damage to progress undetected. Inform your doctor about all medications you are taking, particularly antiepileptic drugs and methotrexate.
While folic acid is generally considered a safe medication with a wide therapeutic margin, there are several important considerations that patients and healthcare providers should be aware of before initiating treatment. The most significant concern relates to the interaction between folic acid supplementation and vitamin B12 (cobalamin) deficiency, a relationship that has important clinical implications.
Contraindications
Folsyra Vitabalans should not be used in the following circumstances:
- Hypersensitivity to folic acid or any of the excipients in the formulation
- Undiagnosed megaloblastic anaemia: Folic acid must not be used to treat megaloblastic anaemia until vitamin B12 deficiency has been excluded. Administration of folic acid in the presence of undiagnosed B12 deficiency may correct the haematological abnormalities while masking the underlying B12 deficiency, allowing subacute combined degeneration of the spinal cord to develop
- Malignant disease: In patients with folate-dependent tumours, folic acid should be used with caution, as it could theoretically promote tumour growth. However, this remains a theoretical concern and has not been conclusively demonstrated in clinical studies
Warnings and Precautions
Several important precautions apply to the use of folic acid:
- Vitamin B12 deficiency masking: This is the most critical safety concern. Folic acid supplementation can correct the macrocytic anaemia associated with vitamin B12 deficiency without addressing the underlying neuropathy. The British National Formulary (BNF) and other authoritative references strongly recommend measuring serum B12 levels before initiating folic acid therapy for megaloblastic anaemia
- Epilepsy: In patients with epilepsy, folic acid may reduce the effectiveness of antiepileptic medications such as phenytoin, phenobarbital, and primidone. Serum drug levels should be monitored, and anticonvulsant dosage may need adjustment
- Pernicious anaemia: Folic acid is not appropriate as monotherapy for pernicious anaemia. Vitamin B12 must be co-administered
- Stent placement: Some studies have suggested that high-dose folic acid combined with vitamin B12 and vitamin B6 may increase the risk of restenosis after coronary stenting, although evidence remains inconclusive
Never use folic acid to treat anaemia without first confirming that vitamin B12 levels are adequate. Folic acid can normalise the blood count in B12-deficient patients, giving a false sense of improvement while neurological damage from B12 deficiency continues to progress. This can result in irreversible damage to the spinal cord and peripheral nerves. Always request a serum vitamin B12 test before starting folic acid for megaloblastic anaemia.
Pregnancy and Breastfeeding
Folic acid is not only safe during pregnancy but is actively recommended. The World Health Organization (WHO) recommends that all women of reproductive age take 400 micrograms (0.4 mg) of folic acid daily, ideally beginning at least one month before conception and continuing through the first 12 weeks of pregnancy. This recommendation is based on robust evidence from randomised controlled trials demonstrating that periconceptional folic acid supplementation reduces the risk of neural tube defects by approximately 70%.
Women at higher risk of neural tube defect-affected pregnancies – including those with a previous affected pregnancy, those taking antiepileptic medications, those with diabetes mellitus, and those with a body mass index (BMI) above 30 – may be prescribed higher doses, typically 5 mg daily, as recommended by national guidelines including those from the National Institute for Health and Care Excellence (NICE) and the American College of Obstetricians and Gynecologists (ACOG).
Folic acid is excreted in breast milk and is considered compatible with breastfeeding. Adequate folate intake during lactation supports both maternal health and the nutritional needs of the breastfed infant. The recommended dietary allowance (RDA) for lactating women is 500 micrograms of dietary folate equivalents per day.
How Does Folsyra Vitabalans Interact with Other Drugs?
Folic acid interacts with several important drug classes, particularly antiepileptic medications (phenytoin, carbamazepine, phenobarbital), methotrexate, and certain antibiotics (trimethoprim, sulfamethoxazole). These interactions can either reduce the efficacy of the interacting drug or impair folate absorption and metabolism.
Understanding drug interactions with folic acid is clinically important because folic acid occupies a central position in cellular metabolism. Many drugs exert their therapeutic effects by interfering with folate metabolism (antifolates), while others affect folate absorption or utilisation through different mechanisms. The clinical significance of these interactions ranges from minor to potentially dangerous, requiring careful monitoring and dose adjustment.
Major Interactions
| Interacting Drug | Mechanism | Clinical Effect | Management |
|---|---|---|---|
| Methotrexate | Inhibits dihydrofolate reductase | Folic acid may reduce methotrexate efficacy; methotrexate depletes folate stores | Time doses carefully; take folic acid 24-48 hours after methotrexate. Do not take on the same day |
| Phenytoin | Mutual interference with metabolism | Folic acid may reduce phenytoin levels; phenytoin lowers folate | Monitor phenytoin serum levels; may need dose adjustment of both drugs |
| Carbamazepine | Enzyme induction reduces folate; folic acid may alter drug levels | Reduced anticonvulsant efficacy; folate depletion | Monitor anticonvulsant levels and adjust doses accordingly |
| Phenobarbital | Similar to phenytoin interaction | Folic acid may reduce phenobarbital efficacy | Monitor serum levels of anticonvulsant |
| Sulfasalazine | Inhibits intestinal absorption of folate | Reduced folate levels, increased risk of deficiency | Supplement with folic acid; monitor folate status |
Minor Interactions
Several other medications have documented but generally less clinically significant interactions with folic acid:
- Trimethoprim and co-trimoxazole: These antibiotics inhibit dihydrofolate reductase and can reduce folate levels with prolonged use. Folic acid supplementation may be considered during long-term therapy
- Cholestyramine: This bile acid sequestrant may reduce folic acid absorption. Doses should be separated by at least 4–6 hours
- Oral contraceptives: Combined oral contraceptives may slightly reduce serum folate levels, though the clinical significance is generally minimal for most women
- Antacids and proton pump inhibitors: May impair folic acid absorption at high pH. The clinical significance is usually minor with normal dietary intake
- 5-fluorouracil: Folinic acid (leucovorin, not folic acid) is used to modulate the effects of 5-fluorouracil in cancer chemotherapy. Folic acid should not be substituted for folinic acid in this context
What Is the Correct Dosage of Folsyra Vitabalans?
The dosage of Folsyra Vitabalans varies depending on the indication. For folate deficiency anaemia in adults, the typical dose is 5 mg daily for four months. For pregnancy prevention of neural tube defects, 400 micrograms to 5 mg daily is recommended depending on risk level. Each tablet contains 1 mg of folic acid. Always follow your doctor's specific dosage instructions.
Folic acid dosing is highly dependent on the clinical indication, the patient's age, and any concurrent medical conditions or medications. The 1 mg tablet strength of Folsyra Vitabalans provides flexibility in dosing, as patients can take multiple tablets to achieve higher doses when needed, or the tablet may be halved (if the formulation allows) for lower doses. However, it is important to note that for the standard pregnancy prophylaxis dose of 400 micrograms, a lower-strength supplement may be more convenient.
Adults
Folate Deficiency Anaemia
Dose: 5 mg daily for 4 months (maintenance dose may be 5 mg every 1–7 days thereafter)
Treatment is typically initiated at 5 mg daily. A clinical response, demonstrated by a rise in reticulocyte count within 5–7 days and normalization of haemoglobin over 1–2 months, confirms folate deficiency as the cause. The full 4-month treatment course ensures replenishment of body folate stores, which typically hold 5–10 mg of folate.
Prevention of Neural Tube Defects
Standard risk: 400 micrograms (0.4 mg) daily – start at least 1 month before conception, continue through first 12 weeks of pregnancy
High risk: 5 mg daily – for women with previous NTD-affected pregnancy, taking antiepileptics, with diabetes, or BMI >30
Methotrexate Co-therapy
Dose: 5 mg once weekly, taken 24–48 hours after the methotrexate dose
Some rheumatologists prefer 1 mg daily on non-methotrexate days. The goal is to reduce methotrexate-related side effects (stomatitis, gastrointestinal symptoms, hepatotoxicity) without compromising drug efficacy.
Chronic Haemolytic Anaemias
Dose: 5 mg every 1–7 days, adjusted based on the severity of haemolysis and folate levels
Children
Folic acid dosing in children depends on age and the underlying condition:
- Infants under 1 year: 500 micrograms per kilogram of body weight daily, or 50 micrograms daily for folate-deficient megaloblastic anaemia
- Children 1–18 years: For folate deficiency treatment, doses of 250 micrograms to 1 mg daily are typically used, increasing to 5 mg daily for significant deficiency. The dose is adjusted based on age, weight, and clinical response
- Adolescents: May receive adult doses for specific indications following medical assessment
Elderly
Elderly patients may be at increased risk of folate deficiency due to reduced dietary intake, impaired absorption, and polypharmacy. Standard adult dosing applies, but particular attention should be paid to excluding vitamin B12 deficiency before initiating treatment, as both B12 and folate deficiency become more prevalent with age. Elderly patients on multiple medications should have their drug regimen reviewed for potential interactions with folic acid.
Missed Dose
If you miss a dose of Folsyra Vitabalans, take it as soon as you remember on the same day. If it is already close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for a forgotten dose. As a water-soluble vitamin, occasional missed doses of folic acid are unlikely to cause clinically significant problems, but consistent daily intake is important for maintaining adequate folate stores, particularly during pregnancy.
Overdose
Folic acid has very low toxicity and overdose is unlikely to cause serious adverse effects. Doses of up to 15 mg daily have been used in clinical studies without significant toxicity. However, at very high doses (above 5 mg daily over prolonged periods), the following considerations apply:
- Risk of masking vitamin B12 deficiency increases
- Gastrointestinal disturbances may occur
- Sleep disturbances, irritability, and confusion have been reported rarely at very high doses
- May interfere with the efficacy of antiepileptic drugs
In the event of significant overdose, management is largely supportive. There is no specific antidote, but none is generally required given the low toxicity profile. Contact your healthcare provider or local poisons information centre for guidance if overdose is suspected.
What Are the Side Effects of Folsyra Vitabalans?
Folic acid is generally very well tolerated with few reported side effects. The most commonly reported adverse effects are mild gastrointestinal symptoms such as nausea, bloating, and flatulence. Allergic reactions are rare but can include skin rash, itching, and, very rarely, anaphylaxis. At standard therapeutic doses, folic acid is considered one of the safest prescription supplements.
The safety profile of folic acid is well established through decades of clinical use and extensive research. Adverse effects are uncommon at recommended doses, and serious reactions are extremely rare. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) both recognise folic acid as having a favourable safety profile. The following classification of adverse effects is based on frequency categories used by the Council for International Organizations of Medical Sciences (CIOMS) and the EMA.
Uncommon Side Effects
- Nausea
- Abdominal bloating and distension
- Flatulence
- Loss of appetite
- Bitter or unpleasant taste in mouth
Rare Side Effects
- Allergic skin rash (urticaria, erythema)
- Pruritus (itching)
- Sleep disturbances
- Irritability and excitability
- Depression (at high doses)
- Bronchospasm (very rare)
- Anaphylactic reaction (extremely rare)
It is important to distinguish between side effects of folic acid itself and the consequences of folic acid masking vitamin B12 deficiency. The neurological deterioration that can occur when folic acid is given to a B12-deficient patient is not a side effect of folic acid per se, but rather a consequence of delayed diagnosis and treatment of the underlying B12 deficiency.
Long-term safety data from large epidemiological studies, including meta-analyses published in the Cochrane Database, have not identified significant long-term adverse effects from folic acid supplementation at recommended doses. Some observational studies have raised concerns about a possible association between high-dose folic acid supplementation and colorectal cancer risk, but randomised controlled trials and systematic reviews have not confirmed this association at standard supplementation doses.
While side effects from folic acid are rare, you should contact your healthcare provider if you experience any signs of an allergic reaction (such as skin rash, swelling of the face or throat, difficulty breathing) or if you develop any new or worsening symptoms while taking this medication. If you suspect a serious allergic reaction, seek immediate medical attention.
How Should You Store Folsyra Vitabalans?
Store Folsyra Vitabalans at room temperature (below 25°C), protected from light and moisture. Keep the tablets in their original packaging until use. Do not use after the expiry date printed on the packaging. Keep out of the sight and reach of children.
Proper storage of folic acid tablets is important to maintain their potency and safety throughout the product's shelf life. Folic acid is a relatively stable compound under normal conditions, but exposure to certain environmental factors can accelerate degradation.
Specific storage recommendations:
- Temperature: Store at room temperature, ideally below 25°C (77°F). Avoid exposure to excessive heat
- Light protection: Folic acid is photosensitive and degrades when exposed to ultraviolet light. Keep tablets in their original blister pack or container to minimise light exposure
- Moisture: Protect from humidity. Do not store in bathrooms or other humid environments. Keep the container tightly closed
- Expiry date: Do not use tablets after the expiry date (EXP) stated on the packaging. The expiry date refers to the last day of that month
- Disposal: Do not dispose of unused medicines via household waste or wastewater. Return unused tablets to your pharmacy for proper disposal in accordance with local regulations
Folic acid tablets that have changed colour, become soft, or show any signs of deterioration should not be used. If you notice any changes in the appearance of your tablets, consult your pharmacist before continuing use.
What Does Folsyra Vitabalans Contain?
Each Folsyra Vitabalans tablet contains 1 mg of folic acid (pteroylglutamic acid) as the active ingredient. The tablets also contain standard pharmaceutical excipients that serve as binders, fillers, and coating agents to ensure consistent tablet quality and drug release.
The active pharmaceutical ingredient in Folsyra Vitabalans is synthetic folic acid, chemically known as pteroylglutamic acid (PGA). This is a crystalline, yellow-orange powder that is sparingly soluble in water. The 1 mg dose provides approximately 2.5 times the recommended dietary allowance (RDA) of folate for most adults, making it appropriate for both therapeutic and prophylactic uses.
Active Ingredient
- Folic acid (pteroylglutamic acid): 1 mg per tablet
Excipients
The excipients (inactive ingredients) typically found in folic acid tablet formulations include:
- Microcrystalline cellulose: Used as a filler and binder to provide tablet structure
- Lactose monohydrate: A filler that contributes to tablet weight and uniformity (patients with lactose intolerance should discuss this with their pharmacist)
- Magnesium stearate: A lubricant that prevents the tablet from sticking to manufacturing equipment
- Maize starch or potato starch: Disintegrant that helps the tablet break apart for absorption
- Povidone: A binding agent that holds the tablet together
Some folic acid tablet formulations contain lactose. If you have known lactose intolerance or galactose malabsorption, consult your pharmacist or doctor about the excipient composition. The product does not typically contain gluten, but always check the patient information leaflet for the most up-to-date excipient list specific to your batch.
Frequently Asked Questions About Folsyra Vitabalans
Folsyra Vitabalans contains 1 mg of folic acid and is primarily used to treat and prevent folate deficiency anaemia. It is commonly prescribed during pregnancy to prevent neural tube defects such as spina bifida, and may also be used alongside methotrexate therapy to reduce side effects. It is also used in patients with chronic haemolytic anaemias and those undergoing dialysis who are at risk of folate depletion.
Yes, folic acid is strongly recommended during pregnancy. The WHO recommends all women take 400 micrograms daily from the time they begin trying to conceive through the first 12 weeks of pregnancy. Women at higher risk (previous NTD-affected pregnancy, epilepsy medication, diabetes, BMI >30) may need up to 5 mg daily. Folic acid is also considered safe and beneficial during breastfeeding, as it supports both maternal health and the nutritional needs of the infant.
For folate deficiency anaemia, a reticulocyte response (indicating new red blood cell production) typically occurs within 5–7 days of starting treatment. Haemoglobin levels generally begin to normalise within 2–4 weeks and reach normal values within 1–2 months. The full treatment course of 4 months is needed to fully replenish body folate stores. For pregnancy prevention purposes, folic acid should ideally be started at least 1 month before conception to build adequate folate stores.
Vitamin B12 deficiency and folate deficiency both cause megaloblastic anaemia with similar blood test findings. If folic acid is given to a patient who actually has B12 deficiency, the blood count may improve, falsely suggesting that the anaemia has been treated. Meanwhile, the neurological damage caused by B12 deficiency – including peripheral neuropathy, cognitive impairment, and subacute combined degeneration of the spinal cord – continues to progress and may become irreversible. This is why checking B12 levels is considered mandatory before initiating folic acid for megaloblastic anaemia.
Yes, folic acid is commonly prescribed alongside methotrexate for conditions such as rheumatoid arthritis and psoriasis. However, timing is critical: folic acid should be taken 24–48 hours after the methotrexate dose, never on the same day. This is because methotrexate works by inhibiting folate metabolism, and taking folic acid at the same time could reduce its therapeutic efficacy. Folic acid co-supplementation has been shown to significantly reduce methotrexate-related side effects including mouth ulcers, nausea, and liver enzyme elevations.
Natural dietary sources of folate include dark green leafy vegetables (spinach, kale, broccoli), legumes (lentils, chickpeas, black beans), liver and organ meats, citrus fruits, avocado, asparagus, Brussels sprouts, and beetroot. Many countries also fortify staple foods such as bread, flour, and breakfast cereals with folic acid. However, natural food folate has lower bioavailability (approximately 50%) compared to synthetic folic acid in supplements (approximately 85%), which is why supplementation is recommended when higher intakes are needed.
References and Sources
This article is based on peer-reviewed medical literature and authoritative clinical guidelines. All medical claims are supported by evidence level 1A (systematic reviews and meta-analyses of randomised controlled trials) unless otherwise stated.
- World Health Organization (WHO). Guideline: Daily iron and folic acid supplementation in pregnant women. Geneva: WHO; 2012. Updated 2020.
- European Medicines Agency (EMA). Summary of Product Characteristics – Folic acid containing medicinal products. EMA/CHMP guidelines.
- British National Formulary (BNF). Folic acid. NICE Evidence Services. Accessed January 2026.
- De-Regil LM, Peña-Rosas JP, Fernandez-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database of Systematic Reviews. 2015;(12):CD007950. doi:10.1002/14651858.CD007950.pub3
- National Institute for Health and Care Excellence (NICE). Antenatal care for uncomplicated pregnancies. Clinical guideline [CG62]. Updated 2024.
- American College of Obstetricians and Gynecologists (ACOG). Neural tube defects. Practice Bulletin No. 187. Obstet Gynecol. 2017;130(6):e279–e290.
- Shojania AM. Folic acid and vitamin B12 deficiency in pregnancy and in the neonatal period. Clin Perinatol. 1984;11(2):433–459.
- Visentin M, Diop-Bove N, Zhao R, Goldman ID. The intestinal absorption of folates. Annu Rev Physiol. 2014;76:251–274.
- U.S. Food and Drug Administration (FDA). Folic acid labelling requirements for foods and dietary supplements. FDA Guidance Documents.
- Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet. 2013;381(9871):1029–1036.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians and pharmacists with specialist qualifications in clinical pharmacology, haematology, and obstetric medicine.
Medical Writing
iMedic Medical Editorial Team – Specialists in clinical pharmacology and evidence-based medicine
Medical Review
iMedic Medical Review Board – Independent review according to WHO, EMA, and BNF guidelines
Our editorial process: All medical content on iMedic is written by qualified healthcare professionals, fact-checked against peer-reviewed sources, and independently reviewed by our Medical Review Board. We follow the GRADE framework for evidence assessment and adhere to international guidelines from WHO, EMA, and BNF. We have no commercial funding or pharmaceutical industry sponsorship.